



^aGroup A (concomitant administration) received a 0.5-mL dose of 9vHPV vaccine at day 1, month 2, and month 6 and a 0.5-mL dose of Tdap-IPV vaccine day 1; Group B (nonconcomitant administration) received 9vHPV vaccine at day 1, month 2 and month 6 and Tdap-IPV vaccine at month 1.

Supplementary Figure 1. Subject disposition.